HLAVNÍ TÉMA Alarminy – nové terče biologické léčby bronchiálního astmatu? 358 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2023;69(6):352-358 / www.casopisvnitrnilekarstvi.cz 12. Porsbjerg CM, Sverrild A, Clare M, Lloyd CM, et al. Anti‑alarmins in asthma: targeting the airway epithelium with next‑generation biologics. Eur Respir J. 2020 Nov;56(5):1-14. doi: 10.1183/13993003.00260-2020. 13. Chan R, Stewart K, Misirovs R, et al. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma. J Allergy Clin Immunol Pract. 10(6), June 2022;1497-1505. 14. Liu S, Verma M, Michalec L, Liu W, Sripada A, Rollins D, et al. Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin. J Allergy Clin Immunol. 2018;141:257-68.e6. 15. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24:777-92. 16. Corren J, Gil, GE, Friffiths MJ, et al. Tezepelumab improves patientreported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021,126,2:187-193. 17. Menzies‑Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800-9. 18. Menzies‑Gow A, Brightling CE, Ambrose CS, et al. Effect of tezepelumab in oral corticosteroid‑dependent patients with severe asthma: results from the phase 3 NAVIGATOR study. Am J Respir Crit Care Med. 2021;203:A1442. 19. Wechsler M, Gow AM, Brightling CE, et al. Oral corticosteroid‑sparing effect of tezepelumab in adults with severe asthma. Am J Respir Crit Care Med. 2021;203:A1197. 20. Tezspire 210 mg injekční roztok v předplněné injekční stříkačce. Souhrn údajů o přípravku. Available from: https://www.ema.europa.eu/en/documents/product‑information/tezspire ‑epar‑product‑information_cs.pdf [cit. 27. 7. 2023] 21. Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate‑to‑severe uncontrolled asthma (CASCADE): a double‑blind, randomised, placebo‑controlled, phase 2 trial. Lancet Respir Med. 2021;9:1299-312. 22. Gauvreau G, Hohlfeld J, Boulet L‑P, et al. Late Breaking Abstract—Efficacy of CSJ117 on allergen‑induced asthmatic responses in mild atopic asthma patients. Eur Respir J. 2020;56 (Suppl 64):3690. 23. Zoumot Z, Busaidi Al N, Tashkandi W, et al. Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta‑analysis. J Asthma Allergy. 2022,15:371-379. 24. Préfontaine D, Nadigel J, Chouiali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol. 2010;125:752-4. 25. Cherry WB, Yoon J, Bartemes KR, et al. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121:1484-90. 26. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate‑to‑severe asthma. N Engl J Med. 2021;385:1656-68. 27. Salter BM, Oliveria JP, Nusca G, Smith SG, Tworek D, Mitchell PD, et al. IL- 25 and IL33 induce type 2 inflammation in basophils from subjects with allergic asthma. Respir Res. 2016;17:5. 28. Deng C, Peng N, Tang Y, Yu N, et al. Roles of IL-25 in type 2 inflammation and autoimmune pathogenesis. Front Immunol. 2021;12:691559. 29. Busse WW, Holgate S, Kerwin E, et al. Randomized, double‑blind, placebo‑controlled study of brodalumab, a human anti‑IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294-302. 30. Khatri SB, Iaccarino JM, Barochia A, et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021;204:e97-109. 31. Shrimanker R, Keene O, Hynes G, et al. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med. 2019;200:1308-12. 32. Hearn AP, Kavanagh J, d’Ancona G, et al. The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9:2093-6. 33. FitzGerald JM, Bleecker ER, Menzies‑Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51-64. ODBORNÝ GARANT: prof. MUDr. Michal Vrablík, Ph.D. III. interní klinika 1. LF UK a VFN v Praze POŘADATEL: SOLEN, s. r. o. PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN září 2023 až srpen 2024 dostupný na online.solen.cz On-line kurz Kardiologie ON LINE KURZ PŘEDNÁŠKY Co je u nových tabulek SCORE opravdu důležité? Modelové situace v ordinaci a jak je řešit – MUDr. Jaromír Ožana, MUDr. Michal Mačák Speciality v léčbě hypertenze – doc. MUDr. Ondřej Petrák, Ph.D. Aktuality a praktické tipy v léčbě dyslipidemie – MUDr. Eva Tůmová, Ph.D. Co (ne)budeme potřebovat od biochemické laboratoře pro stanovení kardiovaskulárního rizika? – prof. MUDr. Michal Vrablík, Ph.D.
RkJQdWJsaXNoZXIy NDA4Mjc=